Qin Zheng, Yang Xingsheng, Cheng Wanjun, Wang Jianlong, Jin Zening
Department of Cardiovascular, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Front Cardiovasc Med. 2022 Jun 14;9:913008. doi: 10.3389/fcvm.2022.913008. eCollection 2022.
Radial artery occlusion (RAO) after transradial access is a common thrombotic complication. A meta-analysis has proven that RAO incidence in transradial coronary angiography (TRCA) settings was significantly higher than that in percutaneous coronary intervention settings. This prospective observational cohort aimed to evaluate radial artery protection after TRCA with different antiplatelet strategies.
A total of 2,316 patients undergoing TRCA was enrolled and divided into two groups: single-antiplatelet and dual-antiplatelet groups. Radial artery patency was evaluated by ultrasound before, at 24 h, and 30 days after TRCA. The primary endpoint was RAO incidence at 30 days after TRCA.
A total of 66 RAO was found on ultrasonography at 30-day follow-up (incidence: 2.8%). In the dual-antiplatelet group, the rate of RAO was significantly lower compared with the single-antiplatelet group (1.8 vs. 4.0%; odds ratio (OR): 0.41; 95% confidence interval (CI): 0.24-0.70; = 0.001). The rate of self-recanalization in the dual-antiplatelet group was significantly higher than that in the single-antiplatelet group (73.68 vs. 44.12%, < 0.001). However, there was no statistical difference in delayed occlusion of radial artery between the two groups (0.5 vs. 0.2%, = 0.140). Unexpectedly, this study also showed no significant difference in bleeding risk between the groups.
Dual-antiplatelet therapy for 1 month after TRCA was associated with a reduced risk of RAO and deemed safe.
经桡动脉途径术后桡动脉闭塞(RAO)是一种常见的血栓形成并发症。一项荟萃分析证明,经桡动脉冠状动脉造影(TRCA)情况下的RAO发生率显著高于经皮冠状动脉介入治疗情况下的发生率。这项前瞻性观察性队列研究旨在评估采用不同抗血小板策略的TRCA术后桡动脉的保护情况。
共纳入2316例行TRCA的患者,并将其分为两组:单药抗血小板组和双联抗血小板组。在TRCA术前、术后24小时和30天时通过超声评估桡动脉通畅情况。主要终点是TRCA术后30天的RAO发生率。
在30天随访的超声检查中总共发现66例RAO(发生率:2.8%)。双联抗血小板组的RAO发生率显著低于单药抗血小板组(1.8%对4.0%;优势比(OR):0.41;95%置信区间(CI):0.24 - 0.70;P = 0.001)。双联抗血小板组的自行再通率显著高于单药抗血小板组(73.68%对44.12%,P < 0.001)。然而,两组之间桡动脉延迟闭塞情况无统计学差异(0.5%对0.2%,P = 0.140)。出乎意料的是,本研究还表明两组之间出血风险无显著差异。
TRCA术后1个月的双联抗血小板治疗与降低RAO风险相关且被认为是安全的。